canyon landscape

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE)

A phase 3, double-blind, placebo-controlled, randomized-withdrawal study of the efficacy and safety of relacorilant.


This study will evaluate the efficacy and safety of GR antagonism by relacorilant, with an emphasis on two robust and validated endpoints, blood glucose control and blood pressure (BP) control, in patients with endogenous Cushing syndrome. To examine the many manifestations of Cushing syndrome in the study patients, several other efficacy assessments will be used to assess clinical benefit. 

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Corcept Therapeutics
Contact Us

Enrollment Information

Contact Marie Catherine O’ Hagan at (602) 406-1782